42 results about "Pulmonary Macrophages" patented technology

The invention discloses a diterpenoid compound and the preparing method and application thereof. The diterpenoid compound is obtained by using aralia melanocarpa roots as the raw material through extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation. The molecular formula of the diterpenoid compound is C20H30O3. The name of the diterpenoid compound is 14-oxygen-ent-8(9),15-(14-oxo-ent-pimara-8(9),15-diene-19-oic acid). The structural formula is as shown in the specification. According to the preparing method, aralia melanocarpa roots are used as the raw material, and extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation are conducted to generate the diterpenoid compound. The diterpenoid compound can be applied to preparation of anti-inflammatory drugs for prevention and/or treatment. The diterpenoid compound is subjected to in-vitro anti-inflammatory activity testing, and experimental results show a good lipopolysaccharide (LPS) restraining effect and a good effect of inducting pulmonary alveolar macrophages (RAW264.7) to generate NO. A new compound or lead compound with high application value can be provided for the medical industry.

Methods and devices for delivering aerosolized formulations containing polynucleotides to specified regions within a subject's respiratory tract are disclosed. The methods find use in the delivery of ribozymes, antisense polynucleotides, and DNA and RNA expression vectors into airway epithelial cells, alveoli, pulmonary macrophages and other cells in the respiratory tract (including the oropharynx, nose, nasopharynx). These methods may be used for optimization of transfection efficiency and expression in vivo, and for in vivo expression, for example for generating an immune response, or inducing immunological tolerance.

Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (−/−) mice. The SP-D (−/−) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (−/−) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.

A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.

Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.

The invention discloses a PRRSV attenuated strain which is capable of inducing pig body to relatively early generate interferon and a neutralizing antibody and possesses wide-spectrum immunogenicity. The porcine reproductive and respiratory syndrome virus (PRRSV) attenuated strain obtained through separation, passage and attenuation is named as HP-PRRSV-LZ-F65, and is prepared by subculturing PRRSV isolated virus in primary porcine alveolar macrophage for 5 generations and in MARC-145 cell for 60 generations and then performing attenuation, and the homologous rates of HP-PRRSV-LZ-F65 with PRRSV VR-2332 and VR-2385 are respectively 97.50% and 98.2%. Experiments prove that PRRSV-LZ-F65 is capable of relatively early inducing a pig body to generate an anti-PRRSV neutralizing antibody with the level substantially higher than that of other same-kind vaccines, and also is capable of preventing challenge infection of homologous type and heterogenous type PRRSV, and possesses stable gene after being subcultured in vitro for 50 generations. The attenuated strain HP-PRRSV-LZ-F65 and passage strains thereof possess wide application prospect to prevent porcine reproductive and respiratory syndrome as safe efficient wide-spectrum vaccine strain candidates.

The invention discloses application of total polysaccharides of Radix Platycodonis in the preparation of drugs to treat CCCP-induced (carbonyl cyanide 3-chlorophenylhydrazone induced) apoptosis. A mitochondrial pathway-induced apoptosis model is established with CCCP to study influence of the total polysaccharides of Radix Platycodonis upon cell activity and apoptosis after CCCP-induced oxidativeinjury occurs to porcine alveolar macrophages. It is discovered herein for the first time that the total polysaccharides of Radix Platycodonis having a certain concentration (100-200 mu g/mL) can antagonize CCCP-induced apoptosis, nuclear deformation is relieved evidently, and change in the potential of mitochondrial membrane can be inhibited. The pharmaceutical uses of the total polysaccharides of Radix Platycodonis are expanded herein; the development of novel indication drugs using total polysaccharides of Radix Platycodonis as effective ingredients is benefited.

The invention discloses a porcine immortalized alveolar macrophage cell line for expressing a porcine reproductive and respiratory syndrome virus, PRRSV, acceptor CD163. The cell line is named as PAM-Tang-20 which is preserved in CGMCC, the preservation number of culture of which being CGMCC No. 13591. Experiments verify that the cell line established by the invention can express the CD163 acceptor highly, is a susceptible cell of PRRSV, and can be widely applied to proliferation of PRRSV, separation of PRRSV clinical strains, vaccine production, PRRSV related basic researches and the like. The cell line for provides an effective technical means for in vitro culture of the PRRSV.

The invention discloses a method for constructing an oxidative stress model for a porcine circovirus 2 (PCV2) in-vitro-infected porcine alveolar macrophage. The method comprises the steps of arranging a cell control group and a PCV2 infected group, separately adding an RPMI 1640 nutrient solution and a viral solution of corresponding concentration into each group, carrying out cell adsorption for 2 hours, then, discarding the solutions, adding 1mL of the RPMI 1640 nutrient solution containing 5% of FBS to each group, continuing to carry out culture, separately collecting samples, and applying the samples to the determination on cell activity and cell redox state related indexes. The model has the characteristics of convenience in constructing, relatively low cost, high practicability and the like, a relatively ideal in-vitro model is provided for researching whether PCV2 infection can cause the change of a redox state of an immunocyte or not and an action mechanism of the PCV2 infection, and then, some new thinking may be provided for the treatment on PCV2 infection induced animal diseases.

The invention belongs to the technical field of medicine, and in particular, relates to a use of beta-nicotinamide mononucleotide or a precursor thereof in preparation of medicines or health productsfor treating or alleviating respiratory disorders or diseases. The technical problem to be solved by the invention comprises that a new alternative scheme is provided for preparation of the medicinesor health products for treating or alleviating the respiratory disorders or diseases, and the technical scheme for solving the technical problem comprises that provided is the use of the beta-nicotinamide mononucleotide or the precursor thereof in preparation of the medicines or health products for treating or alleviating the respiratory disorders or diseases. The beta-nicotinamide mononucleotideor beta-nicotinamide riboside can effectively treat pulmonary diseases such as chronic obstructive pulmonary disease, can significantly alleviate the aging of pulmonary macrophages caused by inhalablegranules, and has a good application prospect.

The invention provides a method for inhibiting PRRSV infection of cells by adopting heme oxygenase 1 (HO-1) for inhibiting the PRRSV infection of the cells and an HO-1 inducer cobalt protoporphyrin (CoPP) and hemin as a blocker. The expression is substantially increased after the infection of highly-pathogenic PRRSV, and the expression is substantially decreased after the infection of classic PRRSV. The expression is substantially increased after a PRRSV-permissive cell African green monkey kidney cell line is infected with the highly-pathogenic PRRSV, and the expression is substantially decreased after the PRRSV-permissive cell African green monkey kidney cell line is infected with classic PRRSV. The CoPP and the hemin are used to induce the HO-1 expression of Marc-145 and pig alveolar macrophage (PAM). Results show that each of the CoPP and the hemin substantially induces the HO-1 expression and inhibits the PRRSV infection of the Marc-145 and the PAM cells.

The invention belongs to the field of biological medicines and discloses an alveolar macrophage-like multifunctional nanoparticle loaded with an aggregation-induced emission photothermal material anda preparation method and use of the alveolar macrophage-like multifunctional nanoparticle. The nanoparticle is obtained by taking an aggregation-induced emission photosensitive molecule 2TPE-2NDTA anda polylactic acid/glycollic acid copolymer as a co-carrier to form a core of a nano-drug and coating the 2TPE-2NDTA and the polylactic acid/glycollic acid copolymer with an alveolar macrophage membrane through a design and synthesis. The nanoparticle also has a characteristics of a photo-thermal agent and can be excited by near-infrared laser, and generated heat is used for photo-thermal killingof novel coronaviruses. Meanwhile, since the alveolar macrophage membrane on an outer layer of a nano-drug has related receptors on a surface, the nano-drug can adsorb SARS-CoV-2 and cytokines, so that a purpose of resisting a cytokine storm is achieved. The alveolar macrophage-like multifunctional nanoparticle can also solve a disadvantage and a deficiency of a poor curative effect in a traditional antiviral treatment scheme and becomes a new antiviral treatment strategy.

The invention relates to a preparation for treating porcine bacterial respiratory diseases and a preparation method thereof. The medicinal composition of the preparation comprises cefquinome sulfate and panax notoginseng saponins. The invention further relates to an injection solution for treating porcine bacterial respiratory diseases. The injection solution is prepared from cefquinome sulfate, panax notoginseng saponins, a suspending agent, a dispersing agent, and injection oil for fixing the volume, wherein the cefquinome sulfate is measured by cefquinome. Cefquinome sulfate and panax notoginseng saponins in a reasonable proportion are firstly used for preparing the preparation for treating porcine bacterial respiratory diseases, wherein the panax notoginseng saponins can be used for improving the phagocytic ability of alveolar macrophages, enhancing the sterilization efficacy of cefquinome sulfate, achieving the anti-fibrosis effect, inhibiting pulmonary fibrous exudation in the porcine bacterial respiratory diseases and effectively relieving the symptom of dyspnea in time.

The invention discloses a probiotic composition as well as a preparation and application of the probiotic composition. The probiotic composition comprises VSL#3, lactobacillus rhamnosus M9 and lactobacillus plantarum P-8 which are mixed in an equal ratio of 1:1:1. The probiotic composition is applied to preparation of a drug for treating or preventing pneumonia, particularly pneumonia caused by respiratory syncytial virus (RSV) infection and infantile bronchopneumonia caused by RSV infection. The probiotic composition can relieve change of lung tissue inflammatory pathologic structures causedby RSV infection and inhibit virus infection process of RSV infection, activate TLR3 and RIG-1 signal pathways in alveolar macrophages to promote production of IFN-beta to inhibit expression of lung inflammation factors, and regulate lung florae and intestinal florae to relieve RSV infection.

The present invention discloses a traditional Chinese medicine composition for treating respiratory tract inflammation and belongs to the field of medicine. The traditional Chinese medicine composition comprises herba lophatheri polyphenols, astragalus polysaccharides, Chinese torreya flavone, timosaponin and a honeysuckle extract. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20-120 parts of herba lophatheri polyphenols, 1-100 parts astragalus polysaccharides, 18-160 parts of Chinese torreya flavone, 10-50 parts of timosaponin and 10-15parts of a honeysuckle extract. The traditional Chinese medicine composition can significantly reduce inflammatory damages of respiratory tract of body caused by dust, protects bronchial epithelial cells and alveolar macrophages, and prevents dust from damaging the respiratory tract.

The invention discloses a pharmaceutical composition of desmopressin acetate, and application of the same to biological medicine. The pharmaceutical composition of desmopressin acetate contains desmopressin acetate and a natural product compound (I) with a novel structure. Individual action of desmopressin acetate or the compound (I) enables the phagocytic function of alveolar macrophages and the vitality of AMPhi endoenzyme to be improved and exerts improvement effect on the immune functions of the lung. Combined action of desmopressin acetate and the compound (I) exerts better improvement effect on the immune functions of the lung, so the pharmaceutical composition can be developed into a drug for improving the immune functions of the lung; and the pharmaceutical composition has outstanding substantive features and substantial progress compared with the prior art.

The invention discloses an siRNA for silencing the expression of a Rongchang pig CD14. Firstly, a porcine alveolar macrophage of a CD14-enhanced green fluorescent protein (EGFP) fusion protein for stably expressing a Rongchang pig CD14 gene is established; next, four siRNAs having different loci and targeting the CD 14 gene are synthesized; then, the four siRNAs are transfected into a CD14-EGFP stable cell line by applying an efficient transfection reagent; and finally, the siRNAs capable of efficiently inhibiting the expression of the Rongchang pig CD14 gene are screened, namely the siRNAs inan article 3 (669) are capable of obviously inhibiting the expression of the Rongchang pig CD14 gene, and therefore, a theoretical basis is provided for researches related to inflammatory diseases caused by treating endotoxin shock, endoxemia and gram-negative bacteria by targeting the Rongchang pig CD14 gene.